Format

Send to

Choose Destination
Pharmacol Ther. 2018 Jan;181:91-100. doi: 10.1016/j.pharmthera.2017.07.005. Epub 2017 Jul 15.

Toxicity profiles of immunotherapy.

Author information

1
Early Phase Trials Unit, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France; Department of Medicine, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France.
2
INSERM U1035, ATIP-AVENIR, Université de Bordeaux, Bordeaux, France; Department of Dermatology and Paediatric Dermatology, National Centre for Rare Skin disorders, Saint-André and Pellegrin Hospital, Bordeaux, France.
3
Early Phase Trials Unit, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France; Department of Medicine, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France. Electronic address: a.italiano@bordeaux.unicancer.fr.

Abstract

Immunotherapies are changing the landscape of advanced solid tumor treatment. These therapies have different mechanisms of action and include oncolytic viruses, checkpoint inhibitors, such as CTLA-4 or PD1/PD-L1 monoclonal antibodies, and CSF-1R antibodies. Given the growing therapeutic impact of these agents in oncology, it is important to better understand their properties. Immunotherapies generate new toxicity profiles that are called immune-related adverse events and require specific management. This review focuses on the mechanisms of action of such side effects, as well as their description and their general management.

KEYWORDS:

Checkpoint inhibitors; Management; Mechanisms; Oncolytic viruses; irAEs

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center